Houston space org to launch experiments aboard first mission into polar orbit

all aboard

Fram2, operated by SpaceX, is targeting to launch Monday, March 31. The crew will conduct six TRISH experiments on board. Photo courtesy TRISH.

Houston's Translational Research Institute for Space Health, or TRISH, will send its latest experiments into space aboard the Fram2 mission, the first all-civilian human spaceflight mission to launch over the Earth’s polar regions.

Fram2, operated by SpaceX, is targeting to launch Monday, March 31, at NASA’s Kennedy Space Center in Florida. The crew of four is expected to spend several days in polar orbit aboard the SpaceX Dragon spacecraft in low Earth orbit. TRISH’s research projects are among 22 experiments that the crew will conduct onboard.

The crew's findings will add to TRISH's Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program and will be used to help enhance human health and performance during spaceflight missions, including missions to the moon and Mars, according to a release from TRISH.

“The valuable space health data that will be captured during Fram2 will advance our understanding of how humans respond and adapt to the stressors of space,” Jimmy Wu, TRISH deputy director and chief engineer and assistant professor in Baylor’s Center for Space Medicine, said in the release. “Thanks to the continued interest in furthering space health by commercial space crews, each human health research project sent into orbit brings us closer to improving crew member well-being aboard future spaceflight missions.”

The six TRISH projects on Fram2 include:

  • Cognitive and Physiologic Responses in Commercial Space Crew on Short-Duration Missions, led by Dr. Mathias Basner at the University of Pennsylvania Perelman School of Medicine. The crew will wear a Garmin smartwatch and a BioIntelliSense BioButton® medical grade device to track cognitive performance, including memory, spatial orientation, and attention before, during, and after the mission.
  • Otolith and Posture Evaluation II, led by Mark Shelhamer at Johns Hopkins University. The experiment will look at how astronauts’ eyes sense and respond to motion before and after spaceflight to better understand motion sickness in space.
  • REM and CAD Radiation Monitoring for Private Astronaut Spaceflight, led by Stuart George at NASA Johnson Space Center. This experiment will test space radiation exposure over the Earth’s north and south poles and how this impacts crew members.
  • Space Omics + BioBank, led by Richard Gibbs and Harsha Doddapaneni at Baylor College of Medicine. The experiment will use Baylor’s Human Genome Sequencing Center's Genomic Evaluation of Space Travel and Research program to gain insights from pre-flight and post-flight samples from astronauts.
  • Standardized research questionnaires, led by TRISH. The test asks a set of standardized research questionnaires for the crew to collect data on their sleep, personality, health history, team dynamics and immune-related symptoms.
  • Sensorimotor adaptation, led by TRISH. The project collects data before and after flight to understand sensorimotor abilities, change and recovery time to inform future missions to the moon.

TRISH, which is part of BCM’s Center for Space Medicine with partners Caltech and MIT, has launched experiments on numerous space missions to date, including Blue Origin's New Shepard rocket last November and Axiom Space's Ax-3 mission to the International Space Station last January.

From Your Site Articles
Houston-based health tech organization had experiments on Blue Origin's last mission. Photo courtesy of Blue Origin

Houston space health nonprofit launches first experiments onboard Blue Origin mission

all aboard

Houston's Translational Research Institute for Space Health, or TRISH, conducted cutting-edge research onboard Blue Origin's New Shepard rocket that launched Friday, November 22.

The NS-28 mission sent private astronauts on an 11-minute suborbital journey past the recognized boundary of space known as the Kármán line, according to Blue Origin's website. While on board, astronauts wore a medical-grade BioButton device, known as a BioIntelliSense, that monitored vital signs and biometric readings.

The findings will add to TRISH's Enhancing eXploration Platforms and ANalog Definition, or EXPAND, program and were the first data sets captured from a suborbital flight.

“This initiative enables TRISH to further our research in space medicine by collecting valuable human health data,” Jimmy Wu, TRISH deputy director and chief engineer and assistant professor at Baylor, said in a statement. “New data from suborbital flights builds our understanding of how the human body responds to spaceflight. This holistic view is key in keeping humans healthy and safe in space.”

The experiments were also TRISH's first on a Blue Origin mission.

TRISH, which is part of BCM’s Center for Space Medicine with partners Caltech and MIT, has launched experiments on numerous space missions to date, with each contributing to its EXPAND platform, which compiles research on human health while in space.

In January, TRISH launched six experiments onboard Houston-based Axiom Space's third private astronaut mission to the International Space Station, known as Ax-3. Prior to that, it also sent experiments on board the Ax-2 in May 2023. The research considered topics ranging from changes in astronauts memory before and after space travel to sleep and motor skills.

TRISH also launched experiments onboard SpaceX's Polaris Dawn mission this fall and on the Inspiration4 all-civilian mission to orbit in 2021.

TRISH published its findings from the Inspiration4 mission in the journal Nature this summer. The study showed that "short-duration missions do not pose a significant health risk" to humans onboard. Read more about the team's findings here.

Earlier this month, TRISH announced the initial selection for its Space Health Ingress Program (SHIP) solicitation. Photo via BCM.edu

Houston organization selects research on future foods in space health to receive $1M in funding

research and development

What would we eat if we were forced to decamp to another planet? The most immediate challenges faced by the food industry and astronauts exploring outside Earth are being addressed by The Translational Research Institute for Space Health (TRISH) at Baylor College of Medicine’s Center for Space Medicine’s newest project.

Earlier this month, TRISH announced the initial selection for its Space Health Ingress Program (SHIP) solicitation. Working with California Institute of Technology and Massachusetts Institute of Technology, the Baylor-based program chose “Future Foods for Space: Mobilizing the Future Foods Community to Accelerate Advances in Space Health,” led by Dr. Denneal Jamison-McClung at the University of California, Davis.

“TRISH is bringing in new ideas and investigators to propel space health research,” says Catherine Domingo, TRISH operations lead and research administration associate at Baylor College of Medicine, in the release. “We have long believed that new researchers with fresh perspectives drive innovation and advance human space exploration and SHIP builds on TRISH’s existing efforts to recruit and support new investigators in the space health research field, potentially yielding and high-impact ideas to protect space explorers.”

The goal of the project is to develop sustainable food products and ingredients that could fuel future space travelers on long-term voyages, or even habitation beyond our home planet.

Jamison-McClung and her team’s goal is to enact food-related space health research and inspire the community thereof by mobilizing academic and food-industry researchers who have not previously engaged with the realm of space exploration. Besides growing and developing food products, the project will also address production, storage, and delivery of the nutrition created by the team.

To that end, Jamison-McClung and her recruits will receive $1 million over the course of two years. The goal of the SHIP solicitation is to work with first-time NASA investigators, bringing new minds to the forefront of the space health research world.

“As we look to enable safer space exploration and habitation for humans, it is clear that food and nutrition are foundational,” says Dr. Asha S. Collins, chair of the SHIP advisory board, in a press release. “We’re excited to see how accelerating innovation in food science for space health could also result in food-related innovations for people on Earth in remote areas and food deserts.”

TRISH is sending six research projects onboard Axiom Space's next mission, which is expected to launch in January. Photo via bcm.com

Space health nonprofit to send 6 more experiments to space on Houston company's next mission

medicine in orbit

A Houston organization announced that it plans to launch six more experiments into space next year that look to learn more about everything from motion sickness to genome alterations during space travel.

The Translational Research Institute for Space Health, or TRISH, which is part of BCM’s Center for Space Medicine, will team up once more with Houston-based Axiom Space on its third private astronaut mission to the International Space Station, Ax-3, which is expected to launch in January. TRISH also sent experiments on Axiom's Ax-2 mission that launched in May.

The experiments are part of TRISH's Enhancing eXploration Platforms and Analog Definition (EXPAND) program, which aims "to help humans thrive on future space missions," according to a release.

“Our commercial spaceflight partners such as Axiom Space are instrumental to cutting-edge research, including these projects designed to reveal how the human body and mind function in the extreme environment of space,” Dr. Emmanuel Urquieta, TRISH chief medical officer, EXPAND program lead and assistant professor in the Center for Space Medicine at Baylor. “This work represents an important step in our journey to understand the body's response to challenging conditions, which is critical for improving human health both here on Earth and on future long-duration missions, including to the Moon and Mars.”

The six project onboard Ax-3 include:

  • Cognitive and Physiologic Responses in Commercial Space Crew on Short-Duration Missions, Mathias Basner, M.D., Ph.D., M.S., University of Pennsylvania Perelman School of Medicine: Basner’s team will track spaceflight participants’ memory, abstraction, spatial orientation, emotion recognition, risk decision-making and sustained attention before and after space travel
  • Otolith and Posture Evaluation II, Mark Shelhamer, Sc.D., Johns Hopkins University: Shelhamer's team will study how inner ears and eyes sense and respond to motion before and immediately after spaceflight to predict who is likely to develop space motion sickness.
  • Space Omics + BioBank, Richard Gibbs, Ph.D., Baylor College of Medicine: Gibbs’ team will gather biological specimens from astronauts before and after their mission to assess the effects of spaceflight on the human body at the genomic level.
  • SANS Surveillance, TRISH: The institute will study Spaceflight Associated Neuro-Ocular Syndrome by collecting vision function data during the ground phases of the mission.
  • Standardized research questionnaires, TRISH: The institute will gather contextual and qualitative data points for its EXPAND research database related to sleep, personality, health history, team dynamics and immune-related symptoms.
  • Sensorimotor adaptation, TRISH: The institute will collect data on how spaceflight participants' ability to stand, balance and have full body control.

Ax-3 is Axiom's third commercial astronaut mission to the ISS, which the company announced in March. The crew, which includes Commander Michael López-Alegría, Pilot Walter Villadei, and Mission Specialists Alper Gezeravcı and Marcus Wandt, will spend 14 days on the ISS. The mission will launch from NASA’s Kennedy Space Center in Florida aboard a SpaceX Dragon spacecraft.

Axiom also has plans for its fourth private mission, Ax-4, which it announced in August.

In addition to the partnership with Axiom, TRISH also announced late last month that it has made a new agreement with the Australian Antarctic Division's Polar Medicine Unit. The collaboration will nominate pilot projects that focus on challenges associated with extreme isolation, which have applications in long-duration space travel to the Moon and Mars.

“Our international collaboration with the AAD will extract insights to benefit all future astronauts, as well as other explorers of extreme environments,” said Dr. Dorit Donoviel, associate professor in the Center for Space Medicine at Baylor and TRISH executive director. “This agreement marks the beginning of yet another exciting venture into space health research for TRISH, and we look forward to collaborating with the AAD to advance our shared goal of promoting safe human exploration.”

In March, TRISH also announced an international agreement with the Korea National Institute of Health. The two organizations plan to collaborate on research related to mental health issues due to space travel, the challenges of food supply in deep space, the negative effects of space radiation and en-suite medical care for long-duration space travel.

TRISH is also slated to launch nine experiments on board SpaceX's Polaris Dawn mission, which is now expected to launch no earlier than 2024. The research aboard Polaris Dawn is intended to complement research supported by TRISH on the Inspiration4 all-civilian mission to orbit.
TRISH, or the Translational Institute of Space Health, has named three fellows to its new program. Photo via bcm.edu

Houston space health research organization names 3 fellows for bioastronautics program

hello fellows

Three Texas scientists have been selected for a Houston organization's prestigious program focused on space health.

TRISH, or the Translational Research Institute for Space Health, which is based out of Houston-based Baylor College of Medicine, has announced its selections for the TRISH 2023 fellowship. The program, announced last fall, is in partnership with California Institute of Technology and Massachusetts Institute of Technology.

“Supporting the next generation of space health researchers ensures that we will have the best possible data to make evidence-based decisions about managing human systems risk for exploration class missions,” says Dr. Jennifer Fogarty, TRISH’s chief scientific officer, in a news release. “By investing in TRISH postdoctoral fellows, we’re investing in future experts who will strive to solve the complex problems and risks associated with human space exploration. We are thrilled to welcome these accomplished early-career scientists to the TRISH community.”

The three selected postdoctoral fellows are focused on researching within space health — specifically reducing the health risks associated with spaceflight. They will receive a two-year salary stipend and participate in TRISH’s Academy of Bioastronautics, a mentorship community for space health professionals.

“Pursuing my postdoctoral training at TRISH has accelerated my career and expanded my research portfolio, enabling me to make new connections and become a more well-rounded scientist,” says Dr. Evan Buettmann, a TRISH third-year postdoctoral fellow at Virginia Commonwealth University, in the release. “Having completed my Ph.D. in bone regeneration, I didn’t initially anticipate that my studies would lead me to an academic career in space health. TRISH stood out to me as an excellent place to complete my postdoctoral training, as it’s at the cutting edge of both space science and medicine and offers extensive mentorship and leadership opportunities.”

This 2023 cohort of fellows include:

  • Stephanie Dudzinski, M.D., Ph.D. Her research focuses on extending healthy life in space by characterizing radiation-induced pro-inflammatory response and enhancing wound repair and recovery with radiation- mitigating thrombin peptide. Her mentor is Steven Frank, M.D., of the University of Texas MD Anderson Cancer Center.
  • Adrien Robin, Ph.D., who is looking at the effect of deconditioning on-gravitational dose-response curves for cardiovascular and ocular variables in men and women and is being mentored by Ana Diaz Artiles, Ph.D., Texas A&M Engineering Experiment Station.
  • Katherine Wozniak, Ph.D., who is defining gut microbial changes to space-like radiation to develop a radiation-resistant microbiome. Her mentor is Robert Britton, Ph.D., of Baylor College of Medicine.
In addition to supporting scientists through its fellowship program, TRISH is actively conducting research aboard commercial space flights — most recently with Axiom Space's Ax-2 mission..
This week's roundup of Houston innovators includes Emmanuel Urquieta of TRISH, Ariel Jones of Qualtrics XM, and Lawson Gow of Pokatok. Photos courtesy

3 Houston innovators to know this week

WHO'S WHO

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from space health research to sports tech — recently making headlines in Houston innovation.


Dr. Emmanuel Urquieta, chief medical officer of TRISH

Emmanuel Urquieta, chief medical officer of TRISH, joins the Houston Innovators Podcast. Photo via LinkedIn

Since 2021, the Translational Research Institute for Space Health has conducted its research on four missions — which has meant an unparalleled access to space health data for TRISH.

“We really saw the value of implementing research in civilians because they are different from your traditional government astronaut,” Dr. Emmanuel Urquieta, chief medical officer for TRISH, says on the Houston Innovators Podcast. “In civilians, you see a more diverse population.”

Urquieta says TRISH's experiments on these missions all fall within a few pillars of space health, including space's effects on sensory motor skills, like balance and motion sickness, as well as mental health, environmental data from the vehicles, vital monitoring, and more. Read more.

Ariel Jones, head of health care provider solution strategy for Qualtrics XM

As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe. Photo courtesy

In a guest column for InnovationMap, Ariel Jones, head of health care provider solution strategy for Qualtrics XM, addresses inequalities in health care — and how technology, specifical experience management tech, can help bridge the gap.

"As the health care industry continues to evolve, experience management technology will play an increasingly important role in addressing health equity gaps and improving the health and well-being of patients across the globe," she writes. Read more.

Lawson Gow, co-founder of Pokatok

A new sports festival is headed to Houston next year. Photo courtesy of Pokatok

Pokatok, the recently announced, four-day sports festival is slated to take place April 4-7, 2024.

“Pokatok will not only be the largest gathering of the entire sports tech ecosystem, it will also be a true fan festival for sports enthusiasts,” says Gow in the news release. “Everyone speaks the language of sport, it’s an incredibly powerful unifier of our society, and this festival will bring together people from around the world to experience hundreds of events revolving around the new and the next in sport.”

The festival, which has secured support from Houston First, the Greater Houston Partnership, and the Harris County Houston Sports Authority to put on the event, will feature two tracks — one focused on sports innovation and the other surrounding a fan experience. Pokatok X will include an expo and showcase focused on sports innovation, bringing together startups, investors, accelerators, athletes, and industry experts to dive into sports tech. Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-area lab grows with focus on mobile diagnostics and predictive medicine

mobile medicine

When it comes to healthcare, access can be a matter of life and death. And for patients in skilled nursing facilities, assisted living or even their own homes, the ability to get timely diagnostic testing is not just a convenience, it’s a necessity.

That’s the problem Principle Health Systems (PHS) set out to solve.

Founded in 2016 in Clear Lake, Texas, PHS began as a conventional laboratory but quickly pivoted to mobile diagnostics, offering everything from core blood work and genetic testing to advanced imaging like ultrasounds, echocardiograms, and X-rays.

“We were approached by a group in a local skilled nursing facility to provide services, and we determined pretty quickly there was a massive need in this area,” says James Dieter, founder, chairman and CEO of PHS. “Turnaround time is imperative. These facilities have an incredibly sick population, and of course, they lack mobility to get the care that they need.”

What makes PHS unique is not only what they do, but where they do it. While they operate one of the largest labs serving skilled nursing facilities in the state, their mobile teams go wherever patients are, whether that’s a nursing home, a private residence or even a correctional facility.

Diagnostics, Dieter says, are at the heart of medical decision-making.

“Seventy to 80 percent of all medical decisions are made from diagnostic results in lab and imaging,” he says. “The diagnostic drives the doctor’s or the provider’s next move. When we recognized a massive slowdown in lab results, we had to innovate to do it faster.”

Innovation at PHS isn’t just about speed; it’s about accessibility and precision.

Chris Light, COO, explains: “For stat testing, we use bedside point-of-care instruments. Our phlebotomists take those into the facilities, test at the bedside, and get results within minutes, rather than waiting days for results to come back from a core lab.”

Scaling a mobile operation across multiple states isn’t simple, but PHS has expanded into nine states, including Texas, Oklahoma, Kansas, Missouri and Arizona. Their model relies on licensed mobile phlebotomists, X-ray technologists and sonographers, all trained to provide high-level care outside traditional hospital settings.

The financial impact for patients is significant. Instead of ambulance rides and ER visits costing thousands, PHS services often cost just a fraction, sometimes only tens or hundreds of dollars.

“Traditionally, without mobile diagnostics, the patient would be loaded into a transportation vehicle, typically an ambulance, and taken to a hospital,” Dieter says. “Our approach is a fraction of the cost but brings care directly to the patients.”

The company has also embraced predictive and personalized medicine, offering genetic tests that guide medication decisions and laboratory tests that predict cognitive decline from conditions like Alzheimer's and Parkinson’s.

“We actively look for complementary services to improve patient outcomes,” Dieter says. “Precision medicine and predictive testing have been a great value-add for our providers.”

Looking to the future, PHS sees mobile healthcare as part of a larger trend toward home-based care.

“There’s an aging population that still lives at home with caretakers,” Dieter explains. “We go into the home every day, whether it’s an apartment, a standalone home, or assisted living. The goal is to meet patients where they are and reduce the need for hospitalization.”

Light highlighted another layer of innovation: predictive guidance.

“We host a lot of data, and labs and imaging drive most treatment decisions,” Light says. “We’re exploring how to deploy diagnostics immediately based on results, eliminating hours of delay and keeping patients healthier longer.”

Ultimately, innovation at PHS isn’t just about technology; it’s about equity.

“There’s an 11-year life expectancy gap between major metro areas and rural Texas,” Dieter says. “Our innovation has been leveling the field, so everyone has access to high-quality diagnostics and care, regardless of where they live.”

Aegis Aerospace appoints Houston space leader as new president

moving up

Houston-based Aegis Aerospace's current chief strategy officer, Matt Ondler, will take on the additional role of president on Jan. 1. Ondler will succeed Bill Hollister, who is retiring.

“Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers,” Stephanie Murphy, CEO of Aegis Aerospace, said in a news release.

Hollister guided Aegis Aerospace through expansion and innovation in his three years as president, and will continue to serve in the role of chief technology officer (CTO) for six months and focus on the company's technical and intellectual property frameworks.

"Bill has played an instrumental role in shaping the success and growth of our company, and his contributions leave an indelible mark on both our culture and our achievements," Murphy said in a news release.

Ondler has a background in space hardware development and strategic leadership in government and commercial sectors. Ondler founded subsea robots and software company Houston Mechatronics, Inc., now known as Nauticus Robotics, and also served as president, CTO and CSO during a five-year tenure at Axiom Space. He held various roles in his 25 years at NASA and was also named to the Texas Aerospace Research and Space Economy Consortium Executive Committee last year.

"I am confident that with Matt at the helm as president and Bill supporting us as CTO, we will continue to build on our strong foundation and further elevate our impact in the space industry," Murphy said in a news release. "Matt's vision, experience, and understanding of our evolving markets position us to build on our foundation and pursue new frontiers."

Rice University launches new center to study roots of Alzheimer’s and Parkinson’s

neuro research

Rice University launched its new Amyloid Mechanism and Disease Center last month, which aims to uncover the molecular origins of Alzheimer’s, Parkinson’s and other amyloid-related diseases.

The center will bring together Rice faculty in chemistry, biophysics, cell biology and biochemistry to study how protein aggregates called amyloids form, spread and harm brain cells. It will serve as the neuroscience branch of the Rice Brain Institute, which was also recently established.

The team will work to ultimately increase its understanding of amyloid processes and will collaborate with the Texas Medical Center to turn lab discoveries into real progress for patients. It will hold its launch event on Jan. 21, 2026, and hopes to eventually be a launchpad for future external research funding.

The new hub will be led by Pernilla Wittung-Stafshed, a Rice biophysicist and the Charles W. Duncan Jr.-Welch Chair in Chemistry.

“To make a real difference, we have to go all the way and find a cure,” Wittung-Stafshede said in a news release. “At Rice, with the Amyloid Mechanism and Disease Center as a catalyst, we have the people and ideas to open new doors toward solutions.”

Wittung-Stafshede, who was recruited to Rice through a Cancer Prevention and Research Institute of Texas grant this summer, has led pioneering work on how metal-binding proteins impact neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Her most recent study, published in Advanced Science, suggests a new way of understanding how amyloids may harm cells and consume the brain’s energy molecule, ATP.

According to Alzheimer’s Disease International, neurodegenerative disease cases could reach around 78 million by 2030 and 139 million by 2050. Wittung-Stafshede’s father died of dementia several years ago.

“This is close to my heart,” Wittung-Stafshede added in the news release. “Neurodegenerative diseases such as dementia, Alzheimer’s and Parkinson’s are on the rise as people live longer, and age is the largest risk factor. It affects everyone.”
View All Listings